Last updated on October 2019

This is an Exploratory Study to Evaluate the Safety, Tolerability, and Efficacy of SNA-120 (Pegcantratinib) Ointment for the Symptomatic Treatment of Persistent Pruritus (Itch) and Psoriasis in Subjects Being Treated with Calcipotriene Ointment.


Other Details:

The study staff at Center for Clinical Studies is available to answer any questions you have regarding this study. To learn more or to see if you qualify, please call us at 281-333-2288, select option 2.

COMPENSATION
All study tests, examinations, and medical care required as part of this study are provided at no cost to you, the public health plan (for Canadian residents), or your private medical insurance (if any).

POTENTIAL BENEFITS OF PARTICIPATING IN THE STUDY
You should not expect any benefit from taking part in this study. Your condition may get better, stay the same, or get worse. You may benefit from the medical monitoring (e.g. physical examination, laboratory tests) that is part of the study. The information from this study may help our understanding of the safety of SNA-120 and its potential effectiveness in subjects with psoriasis. This may contribute to the advancement of knowledge in the field of dermatology. If you take part in this study, other people with psoriasis may be helped.

INFORMATION ABOUT THE STUDY
Sienna Biopharmaceuticals Inc. is sponsoring this study. This study will be performed in 4 parts: Screening, Part A, Part B and Follow-up. This study will enroll approximately 86 adult subjects with psoriasis into Part A of the study, and approximately 60 adult subjects into Part B. Approximately 10 centers in United States and Canada will participate.



Find a site near you

Start Over

Center for Clinical Studies

1401 Binz Street, Suite 200 Houston, TX USA
  Connect »